» Articles » PMID: 21786180

MiR-203 Expression Predicts Outcome After Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Liver

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 2011 Jul 26
PMID 21786180
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Many recent studies have shown the utility of microRNAs (miRs) as cancer-related biomarkers. The aim of the present study was to evaluate the correlation between miR-203 expression and prognosis of patients with hepatocellular carcinoma (HCC) and cirrhosis after liver transplantation (LT). Sixty-six HCC samples from patients who had undergone LT were examined for miR-203 expression using quantitative reverse transcription-polymerase chain reaction. The data were correlated with clinicopathological parameters and prognosis. Patient survival was analyzed by the Kaplan-Meier method and log-rank test. Cox regression was used for multivariate analysis of prognostic factors. We found that miR-203 expression was low in tumor tissues of patients (n = 16) with post-LT HCC recurrence in comparison with those in patients with non-recurrence (n = 50) (P = 0.003). Patients with higher miR-203 expression had significantly better recurrence-free survival (RFS) and overall survival (OS) (P = 0.016 for RFS; P = 0.014 for OS). Multivariate analysis revealed that high-miR-203 expression was an independent predictor of good prognosis (HR 0.202, P = 0.006 for RFS; HR 0.332, P = 0.013 for OS). Our results suggest that miR-203 could be a novel prognostic marker in HCC patients who have undergone LT and might also be a potential therapeutic target.

Citing Articles

Independent prognostic significance of tissue and circulating microrna biomarkers in hepatocellular carcinoma.

Jeng L, Chan W, Teng C Discov Oncol. 2025; 16(1):281.

PMID: 40056315 PMC: 11890906. DOI: 10.1007/s12672-025-02043-y.


Molecular Clues for Prediction of Hepatocellular Carcinoma Recurrence After Liver Transplantation.

Badwei N J Clin Exp Hepatol. 2023; 13(5):804-812.

PMID: 37693263 PMC: 10482986. DOI: 10.1016/j.jceh.2023.02.006.


Bio-diagnostic performances of microRNAs set related to DNA damage response pathway among hepatitis C virus-associated hepatocellular carcinoma patients.

Abdo S, Shousha W, Mohamed A, Elshobaky M, Saleh M, Ali M J Genet Eng Biotechnol. 2023; 21(1):85.

PMID: 37587273 PMC: 10432369. DOI: 10.1186/s43141-023-00537-2.


microRNA-203 functions as a natural Ras inhibitor in hepatocellular carcinoma.

Guo J, Li L, Deng N, Xu Y, Wang G, Luo H Am J Cancer Res. 2023; 13(4):1295-1309.

PMID: 37168327 PMC: 10164818.


Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan.

Bhat M, Clotet-Freixas S, Baciu C, Pasini E, Hammad A, Ivanics T Clin Proteomics. 2021; 18(1):27.

PMID: 34794390 PMC: 8600773. DOI: 10.1186/s12014-021-09333-x.


References
1.
Huang J, Qiu Y, Chen G, Huang L, He J . The relationship between Bmi-1 and the epithelial-mesenchymal transition in lung squamous cell carcinoma. Med Oncol. 2011; 29(3):1606-13. DOI: 10.1007/s12032-011-9998-5. View

2.
Ventura A, Jacks T . MicroRNAs and cancer: short RNAs go a long way. Cell. 2009; 136(4):586-91. PMC: 3910108. DOI: 10.1016/j.cell.2009.02.005. View

3.
EDMONDSON H, STEINER P . Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954; 7(3):462-503. DOI: 10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e. View

4.
Viticchie G, Lena A, Latina A, Formosa A, Gregersen L, Lund A . MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle. 2011; 10(7):1121-31. DOI: 10.4161/cc.10.7.15180. View

5.
Li X, Zhang Y, Zhang Y, Ding J, Wu K, Fan D . Survival prediction of gastric cancer by a seven-microRNA signature. Gut. 2009; 59(5):579-85. DOI: 10.1136/gut.2008.175497. View